Real-Life Comparative Effectiveness of IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Multicenter Experience

Alessandro Borghi; Giulia Odorici; Federico Bardazzi; Federica Filippi; Laura Bigi; Claudia Lasagni; Marco Manfredini; Vito Di Lernia; Francesca Peccerillo; Andrea Conti; Rossana Tiberio; Francesca Satolli; Carolina Fantini; Miriam Rovesti; Massimo Gasperini; Michela Tabanelli; Simone D'Adamio; Maria Elena Flacco; Monica Corazza

doi:10.5826/dpc.1403a179

Real-Life Comparative Effectiveness of IL-23 Inhibitors in the Treatment of Moderate to Severe Psoriasis: A Multicenter Experience

Authors

Alessandro Borghi Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
Giulia Odorici Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
Federico Bardazzi Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
Federica Filippi Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy
Laura Bigi Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Claudia Lasagni Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Marco Manfredini Dermatology Unit, Department of Surgical, Medical, Dental and Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
Vito Di Lernia Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda Usl-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Francesca Peccerillo Dermatology Unit, Arcispedale Santa Maria Nuova, Azienda Usl-IRCCS di Reggio Emilia, Reggio Emilia, Italy
Andrea Conti Dermatology Unit, Infermi Hospital, Rimini, AUSL Romagna, Italy
Rossana Tiberio Dermatology Unit, Infermi Hospital, Rimini, AUSL Romagna, Italy
Francesca Satolli Section of Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy
Carolina Fantini Section of Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy
Miriam Rovesti Dermatologic Unit, Ospedale “Guglielmo da Saliceto” di Piacenza PC, Italy
Massimo Gasperini Dermatologic Unit, Ospedale “Guglielmo da Saliceto” di Piacenza PC, Italy
Michela Tabanelli UOC Dermatology of Ravenna, Lugo and Faenza, Italy
Simone D'Adamio UOC Dermatology of Ravenna, Lugo and Faenza, Italy
Maria Elena Flacco Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy
Monica Corazza Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy

Keywords:

Psoriasis, IL23, therapy, effectiveness, real life

References

Mastorino L, Dapavo P, Susca S, Cariti C, Siliquini N, Verrone A, Stroppiana E, Ortoncelli M, Quaglino P, Ribero S. Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment. J Dtsch Dermatol Ges. 2023 Nov

Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat2022;33:2813-2820

Reich K, Gordon KB, Strober B, et al. Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance. J Eur Acad Dermatol Venereol2022;36:2393-2400.

Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, Tildrakizumab and Risankizumab in Real-World Setting: Drug Survival and Effectiveness in the Treatment of Psoriasis and Psoriatic Arthritis. J Dermatolog Treat2022 6:1-24.

Ruggiero A, Fabbrocini G, Cinelli E, et al. Real world practice indirect comparison between guselkumab and risankizumab: Results from an Italian retrospective study. Dermatol Ther.2022;35:e15214.

Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol2022;157(Suppl. 1 to No. 1):1-78.